Individually Tailored Screening of Susceptibility to Sarcopenia Using p53 Codon 72 Polymorphism, Phenotypes, and Conventional Risk Factors

• Published in: Disease markers Vol. 2014; no. 2014; pp. 1 - 10
• Main Authors: Colica, Carmen, Cabibbo, Andrea, Sarlo, Francesca, Gratteri, Santo, Di Renzo, Laura, De Lorenzo, Antonino
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2014; John Wiley & Sons, Inc
• Subjects: Adolescent; Adult; Aged; Body Weight; Codon; Diagnosis; Female; Genetic aspects; Genetic polymorphisms; Health aspects; Humans; Medical screening; Methods; Middle Aged; Models, Genetic; Obesity - complications; Phenotype; Polymorphism, Single Nucleotide; Risk Factors; Sarcopenia; Sarcopenia - complications; Sarcopenia - epidemiology; Sarcopenia - genetics; Tumor proteins; Tumor Suppressor Protein p53 - genetics
• ISSN: 0278-0240; 1875-8630; 1875-8630
• DOI: 10.1155/2014/743634

Background and Aim. p53 activity plays a role in muscle homeostasis and skeletal muscle differentiation; all pathways that lead to sarcopenia are related to p53 activities. We investigate the allelic frequency of the TP53 codon 72 in exon 4 polymorphism in the Italian female population and the association with appendicular skeletal muscle mass index in normal weight (NW), normal weight obese (NWO), and preobese-obese (Preob-Ob) subjects. Methods. We evaluated anthropometry, body composition, and p53 polymorphism in 140 women distinguished in NW, NWO, and Preob-Ob. Results. Arg * / Arg * genotype increases sarcopenia risk up to 20% ( Arg * / Arg * genotype OR = 1. 20; 95% CI = 0. 48– 2. 9; proallele * carriers OR = 0. 83; 95% CI = 0. 83– 2. 06). The risk of being sarcopenic for Arg * / Arg * genotype in NWO and Preob-Ob is 31% higher than NW carriers of proallele * (RR = 0, 31, 95% CI = 0, 15– 0, 66, P = 0, 0079). We developed a model able to predict sarcopenia risk based on age, body fat, and p53 polymorphism. Conclusion. Our study evidences that genotyping TP53 polymorphism could be a useful new genetic approach, in association with body composition evaluations, to assess sarcopenia risk.